SMARCA2 and melanoma: In line with our observation, while no specific mutations unique to melanoma BrM have been identified so far, AKT1E17K increases BrM incidence in mice, and patients with mutations in the PI3K/AKT pathway (e.g., PTEN) have a higher risk of developing central nervous system (CNS) metastases26,35,36.